trial

Long-term Extension Trial of Asenapine in Subjects With Schizophrenia (Study P06125)

NCTId NCT01142596
as of 2026-07-01
Add to landscapeMonitor thisAsk about this
at a glance
Phase 3 · Completed
Enrollment 201 (actual)
Sponsored by Organon and Co
Primary completion 2015-04-22
Synthesized from structured facts only — each point cited above.

Design & status

Phase
Phase 3
Status
Completed
Enrollment
201 (actual)
Study type
Interventional
Allocation
Randomized
Model
Parallel
Masking
Quadruple
Start
2010-05-25
Primary completion
2015-04-22
Eligibility
ALL · 20 Years · 64 Years

Interventions & indications

Drugs
Asenapine

Sponsors

Organon and CoLead Sponsor
Meiji Seika Pharma Co., Ltd.Collaborator

Sites

0 total

Linked catalysts

1
Long-term Extension Trial of Asenapine in Subjects With Schizophrenia (Study P06 — primary completion2015-04-22

Facts & assertions

4 sourced
Enrollment
201
Phase
PHASE3
Primary Completion Date
2015-04-22
Status
COMPLETED
relationships
The graph out of here
drug
Asenapine
drug
lead_sponsor
Organon and Co
company
collaborator
Meiji Seika Pharma Co., Ltd.
company
indication
Schizophrenia
indication
Schizophrenia
indication